

# Laropiprant

Catalog No: tcsc0539



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

571170-77-9

**Formula:**

$C_{21}H_{19}ClFNO_4S$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Alternative Names:**

MK-0524

**Observed Molecular Weight:**


435.9

## Product Description

Laropiprant is a potent, selective **DP receptor** antagonist with  $K_i$  values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.

IC50 & Target:  $K_i$ : 0.57 nM (DP receptor)<sup>[1]</sup>

**In Vitro:** Laropiprant is a potent, selective DP receptor antagonist with  $K_i$  values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively.<sup>[1]</sup> Laropiprant (1  $\mu$ M) causes a significant inhibition of the aggregation but still counteracts the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant blocks DP receptor-dependent increase in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (10  $\mu$ M) and niacin inhibit in vitro thrombus formation <sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!